3 things to know:
1. An evaluation of Sycamore after three months saw pain reduction of about 65 percent according to the pain scales Owestry Disability Index and Visual Analog Scale, according to a Dec. 20 news release.
2. A previous study showed a 40 percent increase in compressive strength between a vertebra instrumented with the Sycamore device and a vertebra that had undergone only a simple balloon kyphoplasty.
3. Safe Orthopaedics expects to launch Sycamore outside the U.S. in January. The company expects FDA approval in the second half of 2022.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
